Trump announces trade deal with EU following months of negotiations
OTTAWA - The University of Ottawa Heart Institute (OHI), Canada’s premier cardiovascular health center, has incorporated Steriwave® nasal photodisinfection into its standard care protocol for cardiac surgeries, Ondine Biomedical Inc. announced today. This move by OHI, known for its comprehensive cardiac care and advanced medical research, aims to enhance patient safety by reducing surgical site infections (SSIs).
Steriwave, developed by Ondine Biomedical (AIM:OBI), utilizes light-activated technology to eliminate nasal pathogens that can lead to SSIs, without contributing to antibiotic resistance. Unlike traditional antimicrobials, Steriwave ensures immediate nasal decolonization, a process that is crucial for patients undergoing surgery.
OHI’s adoption of Steriwave aligns with its reputation for pioneering research and innovative clinical programs. The institute serves as a major referral center for Eastern Ontario, offering advanced cardiac surgery, interventional cardiology, and patient care. Its multidisciplinary teams focus on the prevention, diagnosis, and treatment of heart disease.
According to Carolyn Cross, CEO of Ondine Biomedical, OHI’s decision to integrate Steriwave into its surgical protocols underscores its role as a leader in clinical excellence and patient safety. Cross expressed the company’s pride in partnering with OHI and contributing to their efforts against multidrug resistance.
The introduction of Steriwave at OHI follows successful implementations at other major hospitals in Canada and the UK, including Vancouver General Hospital and Mazankowski Alberta Heart Institute. Clinical deployments have shown a significant drop in SSI rates, further validating the efficacy of Steriwave in infection control.
This advancement in OHI’s patient protection protocols is part of a broader trend among healthcare institutions to adopt innovative solutions that improve surgical outcomes and reduce healthcare costs. The information reported is based on a press release statement from Ondine Biomedical Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.